Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1999 1
2001 2
2002 1
2004 2
2005 2
2006 5
2008 1
2010 1
2011 4
2012 2
2013 1
2015 1
2017 1
2018 1
2020 1
2021 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Seminar on choreas.
Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Cardoso F, et al. Lancet Neurol. 2006 Jul;5(7):589-602. doi: 10.1016/S1474-4422(06)70494-X. Lancet Neurol. 2006. PMID: 16781989 Review.
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichorea in patients with lacunar stroke, but it can be a challenging and complex task in rare autoimmune or genetic choreas. ...Preventive strateg …
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichore …
Huntington's disease: present treatments and future therapeutic modalities.
Bonelli RM, Wenning GK, Kapfhammer HP. Bonelli RM, et al. Int Clin Psychopharmacol. 2004 Mar;19(2):51-62. doi: 10.1097/00004850-200403000-00001. Int Clin Psychopharmacol. 2004. PMID: 15076012 Review.
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless to date, except in a slight symptomatic relief. ...
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless t …
Pharmacological management of Huntington's disease: an evidence-based review.
Bonelli RM, Wenning GK. Bonelli RM, et al. Curr Pharm Des. 2006;12(21):2701-20. doi: 10.2174/138161206777698693. Curr Pharm Des. 2006. PMID: 16842168 Review.
INTRODUCTION: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evidence based review (EBR) of treatment studies has not yet been published. ...
INTRODUCTION: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evid …
Parkinsonism. Multiple system atrophy.
Wenning GK, Quinn NP. Wenning GK, et al. Baillieres Clin Neurol. 1997 Apr;6(1):187-204. Baillieres Clin Neurol. 1997. PMID: 9426875 Review.
Better animal models of MSA and evaluation of novel treatment strategies are urgently required, and grafting techniques currently applied to IPD and Huntington's disease (HD) patients might be usefully combined in MSA. Epidemiological and case-control studies are needed to …
Better animal models of MSA and evaluation of novel treatment strategies are urgently required, and grafting techniques currently applied to …
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.
McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. McNulty P, et al. J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263. J Huntingtons Dis. 2018. PMID: 30103338
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. METHODS: Data were obtained from the European Huntington …
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the re …
The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease.
Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Soliveri P, Lange HW, Weirich-Schwaiger H, Wenning GK, Melegh B, Havasi V, Balikó L, Wieczorek S, Arning L, Zaremba J, Sulek A, Hoffman-Zacharska D, Basak AN, Ersoy N, Zidovska J, Kebrdlova V, Pandolfo M, Ribaï P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhrmann M, Riess O. Metzger S, et al. Neurogenetics. 2006 Mar;7(1):27-30. doi: 10.1007/s10048-005-0023-z. Epub 2005 Dec 21. Neurogenetics. 2006. PMID: 16369839
An expanded polyglutamine stretch in the huntingtin protein has been identified as the pathogenetic cause of Huntington's disease (HD). Although the length of the expanded polyglutamine repeat is inversely correlated with the age-at-onset, additional genetic factors are th …
An expanded polyglutamine stretch in the huntingtin protein has been identified as the pathogenetic cause of Huntington's disease (HD …
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators; Holmans P, Jones L, Tabrizi SJ. Moss DJH, et al. Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. . …
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a qua …
Diffusion-weighted imaging in Huntington's disease.
Seppi K, Schocke MF, Mair KJ, Esterhammer R, Weirich-Schwaiger H, Utermann B, Egger K, Brenneis C, Granata R, Boesch S, Poewe W, Wenning GK. Seppi K, et al. Mov Disord. 2006 Jul;21(7):1043-7. doi: 10.1002/mds.20868. Mov Disord. 2006. PMID: 16570300
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide (CAG) repeat on the huntingtin gene. ...
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide …
Riluzole in Huntington's disease (HD): an open label study with one year follow up.
Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK. Seppi K, et al. J Neurol. 2001 Oct;248(10):866-9. doi: 10.1007/s004150170071. J Neurol. 2001. PMID: 11697523 Clinical Trial.
In an open label study, we administered riluzole (50 mg twice a day) to nine patients with genetically confirmed Huntington's disease (HD) (clinical stages 1-3; mean age 46.4 (SD 9.3) years; mean disease duration 8 (SD 3.3) years). ...
In an open label study, we administered riluzole (50 mg twice a day) to nine patients with genetically confirmed Huntington's disease …
[Predictors of mental and physical quality of life in Huntington's disease].
Brugger F, Hepperger C, Hametner EM, Holl AK, Painold A, Schusterschitz C, Bonelli R, Holas C, Wenning GK, Poewe W, Seppi K. Brugger F, et al. Nervenarzt. 2015 Feb;86(2):167-73. doi: 10.1007/s00115-014-4187-3. Nervenarzt. 2015. PMID: 25659843 German.
BACKGROUND: The assessment of health-related quality of life (hrQoL) is an important tool in therapy studies and in the treatment of patients with Huntington's disease (HD). In the absence of causal interventions, HD therapy targets the alleviation of symptoms aiming to im …
BACKGROUND: The assessment of health-related quality of life (hrQoL) is an important tool in therapy studies and in the treatment of patient …
24 results